Channel
Regulation, reimbursement, privacy, public procurement and policy decisions shaping MedTech adoption.
The U.S. FDA has selected Dexcom as the first participant in the TEMPO digital health device pilot. The AI-driven blood glucose management program will be granted exemption from certain premarket approval requirements, while collecting real-world data through Medicare.
XRHealth acquires digital therapeutics company Swing Therapeutics, integrating the FDA De Novo-authorized Stanza fibromyalgia treatment with its virtual clinic to build a cross-device XR chronic pain management platform, and achieving comprehensive reimbursement through Medicare and commercial insurance.
Analyze the event of Veradigm being sued for patient portal data tracking, and explore the challenges and industry impacts of medical technology companies in data sharing and privacy compliance.
In the third quarter of 2026, the FDA will make approval decisions on multiple biotechnology products, involving areas such as IgA nephropathy, mRNA influenza vaccines, Duchenne muscular dystrophy cell therapy, and gene therapy. These decisions will profoundly impact the direction of the medical technology industry.
PanopticAI obtains FDA's second 510(k) for contactless respiratory rate monitoring; Coreline Soft partners with Mint Medical to advance lung cancer screening AI in Germany; AIRS Medical receives strategic investment to accelerate MRI innovation; QuantumTX and Kaopiz join forces to develop AI-driven preventive healthcare solutions.
China's "Regulations on the Clinical Research and Translational Application of Biomedical New Technologies" (Order 818) establishes a new commercialization pathway for advanced therapies such as cell and gene therapy, allowing clinical translation and charging fees in tertiary hospitals without drug registration from the National Medical Products Administration. This signals China's intention to accelerate local innovation and standardize the drug development environment, and it is expected to become an important player in the development and manufacturing of advanced therapies.
Adcentrx Therapeutics announced that its ADC drug ADRX-0405 has received IND approval from China's NMPA and will be included in Chinese clinical centers to conduct global Phase 1a/1b trials targeting advanced solid tumors, especially prostate cancer. This article analyzes the significance of this technology to the medical industry, market impact, and future outlook.
Amgen is making additional investments in Puerto Rico to expand its biologics manufacturing network, while BioNTech is shutting down some factories in Germany and Singapore and cutting jobs. The different choices made by the two companies reflect how biopharmaceutical manufacturing is shifting from pandemic-driven expansion toward supply chain resilience, capacity efficiency, and a reconfiguration of pipeline priorities.